Effectiveness of Intravenous Isoniazid and Ethambutol Administration in Patients with Tuberculosis Meningoencephalitis and HIV Infection
| Autor: | Mykola Gumenuik, Natalia Nekrasova, Alexandr Peshenko, Kateryna Yurko, Anton Tkachenko, Mykhailo Kuzhko, V. V. Kikinchuk, Yurii Feshchenko, Tetiana Tlustova, Tetiana Butova, Alina Grygorova, Dmytro Butov |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Tuberculosis Gastroenterology Tuberculous meningitis 03 medical and health sciences 0302 clinical medicine Blood serum Internal medicine Isoniazid medicine 030212 general & internal medicine Tuberculous Meningitis Ethambutol business.industry Pyrazinamide medicine.disease Treatment Infectious Diseases 030228 respiratory system Sputum Original Article medicine.symptom business Human Immunodeficiency Virus Rifampicin medicine.drug |
| Zdroj: | Tuberculosis and Respiratory Diseases |
| ISSN: | 2005-6184 1738-3536 |
| DOI: | 10.4046/trd.2019.0021 |
| Popis: | Background The aim of this study was to investigate the effectiveness of intravenous isoniazid (H) and ethambutol (E) administered in patients with new sputum positive drug-susceptible pulmonary tuberculosis (TB) with tuberculous meningoencephalitis (TM) and human immunodeficiency virus (HIV) co-infection in the intensive phase of treatment. Methods Fifty-four patients with TB/TM and HIV co-infection were enrolled for this study. Group 1 comprised of 23 patients treated with E and H intravenously, while rifampicin and pyrazinamide were prescribed orally. Group 2 consisted of 31 patients treated with the first-line anti-TB drugs orally. The concentrations of H and E in blood serum were detected using a chromatographic method. Results A significant improvement in the clinical symptoms and X-ray signs in patients treated intravenously with H and E was observed and compared to group 2. The sputum Mycobacterium tuberculosis positivity was observed during the second month of the treatment in 25.0% of patients from group 1 and 76.1% of the patients from the control group (p=0.003). In addition, nine patients (39.1%) died up to 6 months when H and E were prescribed intravenously compared with 22 (70.9%) in group 2 (p=0.023). Conclusion In TB/TM with HIV, the intravenous H and E treatment was more effective than oral H and E treatment at 2 months of intensive treatment in sputum conversion as well as in clinical improvement, accompanied by significantly higher mean serum concentrations. In addition, the mortality rate was lower in intravenous H and E treatment compared to oral treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|